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excitement in immunotherapy, this therapy 
does not show significant clinical benefit in 
most patients when considering all cancer 
types as a whole (70–80%).[2] Moreover, the 
systemic delivery of the immunotherapy 
and the doses required to induce the host 
immune reactions against cancer can cause 
immune-related adverse effects.[3] Evi-
dence is also emerging that some patients 
(≈9%) become “hyper-progressors” after 
this immunotherapy. These patients show 
extremely poor clinical outcome and accel-
erated tumor growth after single-agent 
checkpoint inhibitor treatment.[4,5] In addi-
tion, late relapses are now emerging as the 
result of longer follow-up of clinical trial 
populations, which suggests the emergence 
of acquired resistance to these treatments.[6] 
A key opportunity is turning nonimmu-
nogenic (cold) tumors into immunogenic 
(hot) tumors. However, the few adjuvants 
(immune potentiators or immunomodula-
tors) that are used for human vaccines in 
licensed products have important draw-
backs for application in cancer immu-
notherapy. They fail to stimulate or are 
weak inducers of the cellular Th1 immune responses and CD8+ 
T-cell responses required to mediate antitumor immunity.[7] 
Consequently, there is urgent need for new approaches to 
enhance the efficacy of vaccine adjuvants for activating immune 
responses against cancer and for combination immunotherapy 
approaches.
Despite the tremendous potential of Toll-like receptor 4 (TLR4) agonists in vac-
cines, their efficacy as monotherapy to treat cancer has been limited. Only some 
lipopolysaccharides (LPS) isolated from particular bacterial strains or structures 
like monophosphoryl lipid A (MPLA) derived from lipooligosaccharide (LOS), 
avoid toxic overactivation of innate immune responses while retaining adequate 
immunogenicity to act as adjuvants. Here, different LOS structures are incorpo-
rated into nanoparticle-filled phospholipid micelles for efficient vaccine delivery 
and more potent cancer immunotherapy. The structurally unique LOS of the 
plant pathogen Xcc is incorporated into phospholipid micelles encapsulating 
iron oxide nanoparticles, producing stable pathogen-mimicking nanostructures 
suitable for targeting antigen presenting cells in the lymph nodes. The antigen is 
conjugated via a hydrazone bond, enabling rapid, easy-to-monitor and high-yield 
antigen ligation at low concentrations. The protective effect of these constructs 
is investigated against a highly aggressive model for tumor immunotherapy. The 
results show that the nanovaccines lead to a higher-level antigen-specific cyto-
toxic T lymphocyte (CTL) effector and memory responses, which when combined 
with abrogation of the immunosuppressive programmed death-ligand 1 (PD-L1), 
provide 100% long-term protection against repeated tumor challenge. This nano-
vaccine platform in combination with checkpoint inhibition of PD-L1 represents a 
promising approach to improve the cancer immunotherapy of TLR4 agonists.
Nanovaccines
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1. Introduction
Cancer immunotherapy, which attempts to harness the specificity 
and power of the immune system against cancer, is revolution-
izing cancer treatment.[1] Although immune checkpoint blockade 
represents a breakthrough and accounts for much of the current 
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Toll-like receptor (TLR) agonists have been studied inten-
sively as potential adjuvants for anticancer vaccines due to 
the known crucial roles of TLRs in both innate and adaptive 
immunity.[8,9] TLR agonists generate immune stimulatory 
effects through the induction of costimulatory molecules 
(CD80, CD86, and CD40) on dendritic cells (DCs) and inflam-
matory cytokines (TNF-α and IL-12) that favor the development 
of Th1 immune responses.[10] However, TLR agonists as mono-
therapies have so far seen limited success when tested in clin-
ical trials, something that has been attributed to dose-limiting 
toxicities owing to systemic cytokine induction[11] and inefficient 
delivery to tumor and draining lymph nodes.[12] Moreover, new 
studies have shown that they can also induce immune inhibi-
tory factors.[13] Improved delivery and blocking these immune 
suppressive effects of TLR agonists provide new opportunities 
to augment the anti-tumor effects of TLR agonists. On the other 
hand, several studies have found that cancer vaccines can sig-
nificantly enhance the effects of checkpoint blockade,[14] and 
therefore combination of targeted cancer vaccines with immune 
checkpoint inhibitors promises to improve the efficacy and 
clinical benefit of immunotherapies. Although various nanopar-
ticles (NPs) have been used as delivery vehicles of TLR agonists, 
the biocompatibility, complexity of synthesis and the efficacy 
when evaluated in animal models varies greatly.[15–22]
Another difficulty to achieve effective antitumor responses 
are cancer cells expressing suboptimal tumor antigen levels.[23] 
This problem may be overcome if the NP also delivers tumor 
antigen to the LN-resident DCs so that they can activate and 
properly present antigen to T-cells to trigger a high-avidity anti-
tumor response.[16,19,20,22,24–26]
To address these issues, here we adopt, optimize, and 
evaluate a micellar-based platform for improved codelivery of 
a TLR4 agonist and OVA as model antigen to the tumor and 
draining lymph nodes together with a strategy to evaluate the 
effect of interfering with the immune checkpoint programmed 
death-ligand 1 (PD-L1) (Scheme 1). Several formulations 
exploiting NPs (quantum dots (QDs), and superparamagnetic 
iron oxide nanospheres and nanocubes) encapsulation in 
polyethylene glycol-phospholipid (PEG-phospholipid) micelles 
were screened for the capture of the TLR4 agonists. The best 
nanovaccine was formulated using 6 nm magnetite NPs, a 
particle size, and a biocompatible and biodegradable material 
already used clinically in contrast agents for diagnosis by mag-
netic resonance imaging (MRI),[27,28] as iron supplement[29] and 
in hyperthermia treatments.[30,31] Moreover, some studies sug-
gest that the intrinsic redox and magnetic properties of iron 
oxide NPs (IONPs) can be applied both to potentiate different 
cancer immunotherapies approaches, including DC-based vac-
cination[32] and macrophage polarization into pro-inflammatory 
M1 phenotypes.[33]
Many studies exploiting NP-mediated antigen delivery used 
amide bond formation between carboxylic acids and amines using 
Small 2019, 15, 1803993
Scheme 1. The pathogen-mimicking magnetite nanoparticles are designed to activate dendritic cells via TLR4 promoting trafficking to the draining lymph 
nodes. When administered with antigen-loaded nanoparticles prepared by a chemoselective ligation strategy, and in combination with the abrogation of 
tumor cell PD-L1 expression, they promote potent antitumor protective immunity. This figure was created using Servier Medical Art templates (https://smart.
servier.com), which are licensed under a Creative Commons Attribution 3.0 Unported License: https://creativecommons.org/licenses/by/3.0/.
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carbodiimide activation (e.g., 1-ethyl-3-(3 dimethylaminopropyl)-
carbodiimide, or EDC); an approach that, to work properly, 
requires high and significant excess of reagents, and suffers from 
poor chemoselectivity and a high degree of cross-linking.[34] Addi-
tionally, the lack of suitable analytical methods to rapidly char-
acterize the NP–antigen conjugates means that these reactions 
can be difficult to optimize, as they have to be performed without 
direct feedback on the progress of the reaction. To overcome 
these limitations, here we applied a bis-aryl hydrazone linkage 
strategy for the coupling of mIONPsp to the model antigen OVA 
with aniline as a nucleophilic catalyst.[35] The hydrazone linkage 
strategy provided important advantages for the formation of the 
antigen–nanoparticle conjugates. The reaction could be conveni-
ently monitored by UV–vis with fast reaction kinetics and high 
yields (>85% in just a few minutes) of conjugation at neutral pH 
and micromolar concentrations, yielding stable conjugates.[34,35]
For development of cancer vaccines, many studies have 
investigated the use of lipopolysaccharides (LPS), which as 
major components of the cell surface of Gram-negative bacteria, 
exert immune stimulatory effects via engagement of TLR4. LPS 
(Figure 1a) is composed of three domains, an amphipathic 
domain known as lipid A, the hydrophilic O-antigen polysac-
charide and a core oligosaccharide (OS) chain, connecting 
lipid A and O-antigen. Lipid A is responsible for the endotoxic 
activity of LPS and derivatives of this domain with reduced 
toxicity have been targets for the development of human vac-
cine adjuvants. Monophosphoryl lipid A (MPLA, Figure 1a), a 
detoxified derivative of Salmonella Minnesota LPS approved by 
the FDA for use in humans, has been evaluated as a cancer vac-
cine adjuvant in a number of clinical trials.[36] The best results 
were obtained with MPLA combined with alum, which led to 
boosted antibody responses.[37–39] However, effective anticancer 
vaccination requires also generation of robust T-cell immunity, 
and these systems have not consistently mediated potent anti-
tumor immunity.[36,40] Lipooligosaccharides (LOS, Figure 1a), 
LPS not possessing the O-antigen chain (named rough LPS), 
have been investigated less for oncological indications.[41] Since 
the immune stimulatory effects and toxicity of LPS and LOS 
greatly vary and are linked to structural variations and phys-
ical states at the supramolecular structure level (i.e., its “state 
of aggregation”), here we explore the potential of Escherichia 
coli LOS and the plant pathogen Xanthomonas campestris pv. 
campestris (Xcc) LOS as anticancer vaccine adjuvants. We rea-
soned that differences in these LPS structures could not only 
affect the biological activity but also regulate the incorpora-
tion into the NP-filled phospholipid micelle delivery vehicles 
(mNPs). Moreover, this would create bacteria-like nanoarchitec-
tures that could be recognized by the host in a way similar to 
the pathogenic agent but exploiting the optimal particle size to 
elicit immune system activation at the tumor and lymph nodes.
The immunosuppressive environment of the tumor has 
proven to be a major obstacle for ligands targeting the TLR4 
signaling pathway to be effective in anti-tumor vaccination. The 
clinical efficacy of checkpoint inhibition on the other hand is 
limited by requiring the existence of antitumor CD8+ T cells at 
the tumor before the checkpoint immunotherapy, with only cer-
tain tumors being immunogenic enough to generate a natural 
antitumor T-cell response. Moreover, even once this natural 
T-cell response is elicited, cancer cells may undergo a series 
of genetic and nongenetic processes to avoid being eliminated 
by the immune system and to acquire resistance to immune 
checkpoint blockade.[6] Insufficient generation of antitumor T 
cells, inadequate function of tumor-specific T cells, impaired 
formation of T-cell memory and cancer immunoediting all 
contribute to monotherapy with checkpoint inhibition being 
ineffective in most cases.
To date, the most effective immune checkpoint inhibitors are 
monoclonal antibodies that bind to either programmed death-1 
(PD-1) or to its ligand PD-L1.[42] The PD-1 receptors expressed 
on activated T cells, on binding to PD-L1, induce a state of inef-
fective T-cell activity. Hence, PD-L1 expression on tumor cells 
confers a potent escape mechanism from the host T-cell immu-
nity. Since the induction of PD-L1 on DCs by TLR ligation has 
been reported for some TLR agonists and shown to be a mecha-
nism limiting the antitumor efficacy of TLR agonists,[13,43,44] we 
reasoned that blocking the immunosuppressive roles of PD-L1 
expression by the tumor would significantly improve the effi-
cacy of the vaccination. Moreover, the induction of PD-L1 is 
linked with the induction and maintenance of Tregs cells,[45,46] 
which are immunosuppressive and increased in cancer 
patients. Thus, blocking one inhibitory factor of PD-L1 may 
decrease other inhibitory factors. To investigate the efficacy of 
the cancer vaccines and nanovaccines and potential synergism 
with PD-L1 checkpoint inhibition arising from the functional 
contributions of tumor cell PD-L1 expression,[47] we previ-
ously used CRISPR/Cas9 genome-editing technology delivered 
within lentiviral particles to abrogate PD-L1 expression only in 
the tumor cells.[48,49]
Here, we have developed a nanovaccine featuring a model 
antigen (OVA) linked to mIONPsp by hydrazone bonds, and an 
adjuvant (Xcc LOS) adhered to the mIONPsp by hydrophobic 
interactions to create pathogen-mimicking nanostructures. The 
protective effect of the OVA linked to mIONPsp via hydrazone 
bond (mIONPsp-HyNic-FB-OVA) formulated with the pathogen-
mimicking mIONPsp-Xcc LOS as adjuvant was investigated in 
vitro and in mice against B16-F10 melanoma expressing OVA. 
The results provide the first evidence that the LOS from Xcc can 
elicit antitumor immune responses and showed that delivery of 
Xcc LOS by mIONPsp improves the immunostimulatory proper-
ties and promotes reduced cytotoxicity. Furthermore, the abroga-
tion of PD-L1 on the tumor cells massively improved the effect 
of vaccination, which conferred 100% long-term immune pro-
tection against multiple tumor challenges.
2. Results and Discussion
2.1. Assembly of Pathogen-Mimicking TLR4 Agonist-Functional-
ized NP Micelles
The encapsulation of hydrophobic IONPsp, QDs, and IONPc 
(cubic iron oxide nanoparticles) in PEG phospholipids with 
incorporation of the two different TLR4 agonists, Xcc LOS (a 
lipooligosaccharide derived from Xanthomonas campestris, a 
plant pathogen) and E. coli LOS (a lipooligosaccharide from 
Escherichia coli) provided micelles that could be stored in an 
aqueous solution for weeks without major aggregation and 
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size changes. In contrast, the incorporation of MPLA imme-
diately afforded insoluble aggregates. The phospholipid–PEG 
and the TLR4 agonists are amphiphilic molecules, which to 
reduce NP/water surface tension associate with the surface of 
the original hydrophobic NPs through interdigitation of their 
acyl chains by van der Waals attractive interactions and create 
Small 2019, 15, 1803993
Figure 1. a) Chemical structures of the TLR4 agonists and b) schematic of the self-assembly process for the synthesis of the water-soluble and 
pathogen-mimicking nanoparticles (NP micelles (mNP) incorporating Xcc or E. coli LOS molecules).
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the self-assembled bacteria-like nanoarchitectures. The organi-
zation of hydrophilic components/precursors at the surfactant/
water interface through electrostatic and hydrogen bonding 
interactions resulted in encapsulation of the NPs in a shell 
formed by the polar head groups, making the pathogen-mim-
icking NP-filled micelles (mNPs) soluble and stable in water 
(Figure 1b). For MPLA, the lack of the hydrophilic O-antigen 
polysaccharide and core oligosaccharide chain might make 
the micelle surface less hydrophilic and increase the surface 
hydrophobicity, which promotes the formation of insoluble 
large aggregates. To remove NP-free micelles, the samples 
were centrifuged (three cycles), the supernatants were kept for 
quantification of LOS and Xcc LOS loading (see below) and the 
pelleted mNPs were redissolved in aqueous solution. The lipoo-
ligosacharide-free mNPs prepared as controls and the path-
ogen-mimicking mNPs incorporating the TLR4 agonists were 
characterized by transmission electronic microscopy (TEM), 
dynamic light scattering (DLS), and by measuring the Z-poten-
tial of the particles (Figure 2 and Figures S1 and S2, Supporting 
Information). The size distribution of bacteria-like TLR4 ago-
nist-functionalized mNPs is in the ideal range (20–100 nm) 
for lymphatic delivery (with a number-averaged hydrodynamic 
diameter of ≈20 nm for IONPsp and QDs and of ≈70 nm for 
IONPc with size polydispersity index between 0.16 and 0.39) 
and they showed a more negative Z-potential than the drug-free 
controls. This result is consistent with the high negative charge 
density of the LOS molecules provided by the phosphate, car-
boxylate, and phosphoramide groups. Also consistent with 
their different structures, the bacteria-like mNPs functionalized 
with Xcc LOS (mIONPsp-Xcc LOS) had a more negative surface 
charge (−11.42 ± 2.17 mV) than mNPs functionalized with E. 
coli LOS (−8.17 ± 1.55 mV). Apart from an optimum size of 
20–100 nm, their negative surface charge provides additional 
advantages for lymph node targeting. Thus, electrostatic repul-
sion with the negatively charged interstitial matrix allows the 
negatively charged particles to move faster through the inter-
stitium and be more efficiently accumulated in the draining 
lymph nodes.[50,51]
Studies have shown also that hydrophobicity facilitates 
both uptake by antigen presenting cells and delivery to lymph 
nodes.[50,52,53] In these constructs bound LOS and the oleic acid 
chains of the NPs provide hydrophobic components to the 
micelle, which upon exposure to the surface can facilitate inter-
action with the membrane of the antigen presenting cells. The 
mIONPsp-LOS therefore possess all the key features of mate-
rials that can effectively target the lymph nodes, namely a size 
Small 2019, 15, 1803993
Figure 2. Size and Z-potential of mIONPsp with and without LOS incorporation. a–c) TEM images and d–f) DLS analysis. g) Main characterization 
data: IONP core diameter from TEM images and counting more than 200 nanoparticles, number-average hydrodynamic diameter and polydispersity 
index obtained by DLS, Z-potential and number of biomolecules per IONP (bottom) based on n > 10 formulation replicates.
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of 20–100 nm, a negative surface and an appropriate level of 
hydrophobicity.
To quantitate TLR4 agonist loading, we carried out two sets 
of experiments. After pelleting the mNP-LPS/LOS systems by 
three cycles of centrifugation, IL-6 cytokine production in the 
macrophage cell line J774A.1 after incubation with the super-
natants was compared with the dose-response curves obtained 
with the corresponding LOS. Since the limulus amebocyte 
lysate (LAL) test is an FDA-approved assay for the determina-
tion of endotoxin in medicines, biological products and medical 
devices, and has been used to detect endotoxin contamination 
in nanomaterials,[54] the quantification of LPS in the super-
natants was also determined by an endpoint chromogenic 
LAL assay. Both assays produced essentially identical results 
(Figure S3, Supporting Information). The results showed 
that the Xcc LOS is incorporated better than the E. coli LOS 
in the mIONPsp and mIONPc (76 ± 6% vs 22.2 ± 5.1% and 
44 ± 11% vs 25 ± 9%, respectively, Figure S4, Supporting Infor-
mation). The mIONPsp could be loaded with 79 ± 5 and 41 ± 2 
molecules of Xcc LOS and E. coli LOS per particle, respectively 
(Figure 2g). The larger NP core size of the mIONPc allowed 
to increase the loading to 240 ± 26 Xcc LOS molecules/particle 
and 76 ± 7 molecules of E. coli LOS/particle (Figure S2g, Sup-
porting Information). Both types of nanoparticles are stabilized 
with an oleic acid/oleylamine surfactant layer. In contrast, the 
commercial QDs with a similar core size to the mIONPsp 
showed preference for incorporating E. coli LOS over Xcc LOS 
(29 ± 1 Xcc LOS molecules/particle vs 155 ± 11 molecules of 
E. coli LOS/particle). This result may reflect the differences in 
the hydrophobic chains, where specific chain lengths etc. con-
tributed to forming more extensive van der Waals interactions 
with the surfactants stabilizing the NPs. Silipo et al. determined 
the complete structure of Xcc LOS and it was found to be a 
unique molecule with high negative charge and variability in 
the fatty acid length and possessing an uncommon symmetric 
(3 + 3) distribution of acyl chains on the disaccharide backbone 
with the acyloxyacyl groups exclusively ester-linked.[55,56]
To study the behavior of the mIONPsp-Xcc LOS over time, the 
size of these constructs was analyzed immediately after purifi-
cation and over a 4 week period in 10 × 10−3 m PBS. Although 
the results showed some aggregation the size of the mIONPsp-
Xcc LOS over time was still within the ideal range for reaching 
the lymph nodes (Figure S5, Supporting Information). To study 
the release of Xcc LOS molecules, at designed time points (week 
0, 1, and 2) 10 × 10−3 m PBS solutions of the mIONPsp-Xcc LOS 
were subjected to centrifugation and the amount of Xcc LOS in 
the supernatant was determined as described below. The results 
showed that only 5% of the Xcc LOS molecules are released. In 
the outer membrane of gram negative bacteria the negatively 
charged LPS molecules cover most of the outer surface and diva-
lent cations such as Mg2+ and Ca2+ are essential to neutralize 
this negative charge and allow strengthening of the lateral inter-
actions between neighboring LPS molecules, which provides 
enhanced stability for the external bacterial membrane.[54,57,58] 
Similar electrostatic interactions and effects such as increased 
hydrogen bonding and tighter lipid packing and cross-linking 
exerted by divalent cation bridging can be expected to take place 
in the pathogen-mimetic mNP–LOS nanostructures to provide 
the observed stability.
2.2. Synthesis and Characterization of OVA Linked to mIONPsp 
via Hydrazone Bond (mIONPsp-HyNic-OVA)
Several studies have improved the immunogenicity of anti-
gens by nanoparticle delivery using N-hydroxysuccinimide 
and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide coupling 
chemistry for the bioconjugation.[21,26,59] Other studies have 
used reductively labile disulfide-based antigen conjugation.[60]
Here, the mIONPsp–antigen conjugates were developed 
by the means of biorthogonal chemistry and hydrazone liga-
tion. The bis-aryl-hydrazone-linking conjugation strategy is 
shown in Figure 3a and offers high chemoselectivity, high 
yields at low concentrations, enhanced reaction rates at pH 
7 (kon = 170 M−1 s−1 in the presence of 100 × 10−3 m aniline) 
and easy reaction monitoring. To introduce the required func-
tional groups onto the mIONPsp, the terminal amine of the 
mIONPsp prepared using 1,2-distearoyl-sn-glycero-3-phosphoe-
thanolamine-N-[amino(polyethylene glycol)-2000] (DSPE–PEG–
amine) was modified to an aromatic hydrazone by reaction with 
the activated ester of the linker succinimidyl 6-hydrazinoni-
cotinate acetone hydrazone (S-HyNic). The HyNic-modified 
mIONPsp (mIONPsp-HyNic) were purified by a desalting 
column and spin filtration. The average molar substitution 
ratio of the mIONPsp with the HyNic linker was ≈10, which 
was determined by reacting mIONPsp-HyNic with 4-nitroben-
zaldehyde and measuring the formation of the bis-aryl hydra-
zone bond at 345 nm. Lysine residues of OVA were modified to 
an aromatic aldehyde by reacting it with the activated ester of 
the linker succinimidyl 4-formylbenzoate (4FB) and purified by 
a desalting column and spin filtration. The substitution ratio of 
the OVA with the 4FB linker was determined by reaction with 
2-hydrazinopyridine-2HCl and measuring the formation of the 
bis-aryl hydrazone at 350 nm, and was 2–3 molecules of 4-FB 
per OVA (Figure 3b). The ligation reaction of the aromatic alde-
hyde functionalized 4FB-OVA (20–30 × 10−6 m) with hydrazine 
activated mIONPsp-HyNic (0.5–3 × 10−6 m IONPs) carried out 
at pH 6.2 and monitored by the hydrazone chromophore for-
mation achieved a high level of conjugation (≈85–90%) in 2 h 
and 80% conversion already within the first 10 min of the reac-
tion in the presence of 100 × 10−3 m aniline catalyst (Figure 3c). 
Quantitative analysis of protein content by BCA showed con-
jugation of 6 molecules of OVA per IONPsp. TEM and DLS 
studies confirmed that this conjugation strategy preserves the 
20–100 nm size for lymph node targeting (Figure 3d,e), and 
that the mIONPsp-HyNic-4FB-OVA are stable for weeks in PBS 
(Figure 3f,g).
2.3. mNP Modulates the Immunostimulatory Properties 
and Cytotoxicity of the TLR4 Agonists
Many studies have shown that the chemical structure dictates 
the immune response to LPS. Moreover, some studies sug-
gest that LPSs as amphiphilic molecules form supra molecular 
aggregates in aqueous environments, and that these struc-
tures are the biologically active units of LPS.[61] However, 
the type of supramolecular aggregate structures formed 
also depends strongly on the chemical structure of the LPS 
molecules.
Small 2019, 15, 1803993
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Incorporation into mNPs ensures the formation of supra-
molecular structures where multiple copies of the LPS mole-
cules are clustered, and therefore we reasoned they would 
show equal or even to be more active than the mNP-free prep-
arations. When stimulating the macrophage cell line J774A.1 
with the different TLR4 ligands in vitro to produce IL-6, the 
biological activity of E. coli LPS showed greater IL-6 produc-
tion in comparison to equal amounts of E. coli LOS or Xcc 
LOS, and lower cell viability. Comparison of IL-6 production 
and cell viability of the TLR4 ligands compared to TLR4 ligand 
loaded mNPs showed that the immunostimulatory properties 
and cytotoxicity are modulated by each of the mNPs differently. 
Small 2019, 15, 1803993
Figure 3. a) General strategy for the conjugation of the antigen (OVA) to mIONPsp. b,c) UV monitoring of the chemical ligations. b) The substitution 
ratio of the OVA with the 4-FB linker was determined by reaction of the FB-OVA with 2-hydrazinopyridine-2HCl. c) The formation of the 4FB-modified 
OVA and the ligation reaction of 4FB-OVA (20–30 × 10−6 m) to mIONPsp-HyNic (0.5–3 × 10−6 m mIONPsp) in presence of ≈100 × 10−3 m of aniline. 
d–g) Size and stability of mIONPsp-HyNic-4FB-OVA. Representative d)TEM micrograph and e–g) DLS analysis of size and size distribution over time.
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Incorporation into mIONPsp enhanced IL-6 production and 
significantly reduced cytotoxicity for Xcc LOS (Figure S6a,b, 
Supporting Information). In contrast, E. coli LOS incorporation 
into mIONPc lead to reduced IL-6 production and significantly 
increased cytotoxicity (Figure S7, Supporting Information). The 
mQDs enhanced IL-6 production without affecting cytotoxicity 
(Figure S8, Supporting Information).
On the basis of these results, we selected for further studies 
the mIONPsp-Xcc LOS system.
Since dendritic cells are the key initiators and modulators 
of the adaptive immune response, the immunostimulatory 
activity was also tested in primary murine bone-marrow-
derived dendritic cells (BMDCs). The results showed Xcc 
LOS and mIONPsp-Xcc LOS to be as effective as E. coli LPS 
and MPLA at inducing IL-6, IL-12, and TNF-α release and 
increasing the expression of costimulatory molecules CD80 
and CD86, and that the mIONPsp alone also have some 
ability to activate DCs (Figure S6c,d, Supporting Information). 
Moreover, the results confirm that when DCs are confronted 
with the TLR4 agonists, inhibitory immune pathways can be 
triggered. The different TLR4 agonists, mIONPsp-Xcc LOS 
and mIONPsp significantly upregulated the expression of the 
inhibitory molecules PD-L1 in DCs (Figure S6d, Supporting 
Information), which is indicative of the potential for synergy 
between the vaccines and PD-L1 checkpoint inhibition. The 
results also showed that mIONPsp-Xcc LOS and mIONPsp-
HyNic-4FB-OVA are essentially nontoxic to DCs (Figure S9, 
Supporting Information).
2.4. mIONPsp-Xcc LOS and mIONPsp-HyNic-4FB-OVA Reach 
Endosomal Compartments
TLR4 is unique, in that it is the only TLR that activates both 
the MyD88- and TRIF-dependent pathways.[62] LPS binding to 
TLR4 induces MyD88- and TRIF-dependent pathways from the 
plasma membrane and endosomes, respectively. It has been 
shown that after TLR4 encounters LPS, endosomes showing 
LPS and TLR4 colocalization appear within 15 min.[63] To 
enable tracking of the mIONPsp during cellular uptake a 5% 
rhodamine B-labeled phospholipid was incorporated during 
the micelle synthesis. As expected, the mIONPsp(Rho)-Xcc 
LOS and mIONPsp(Rho)-HyNic-4FB-OVA colocalized with lys-
osomes in the J774A.1 cells (Figure 4).
2.5. OVA Antigen Delivered by mIONPsp-HyNic-4FB-OVA and 
Formulated with the Pathogen-Mimicking mIONPsp-Xcc LOS 
Provides Enhanced Protection against B16-F10(OVA) Melanoma 
Tumors
B16-F10 melanomas have been widely used as a poorly immu-
nogenic, highly aggressive model for murine tumor immuno-
therapy studies. To investigate the efficacy of Xcc LOS as adjuvant 
evaluating antigen-specific responses, we used the B16-F10 sub-
line engineered to express the model antigen ovalbumin (B16-
F10(OVA)). To the best of our knowledge, the adjuvant properties 
of Xcc LOS for vaccine development and immunotherapy have not 
Small 2019, 15, 1803993
Figure 4. In vitro uptake and trafficking of rhodamine labeled mIONPsp-Xcc LOS and mIONPsp-HyNic-4FB-OVA micelles. a,c) Fluorescence micros-
copy images of J774A.1 macrophages showing endocytic uptake of a) mIONPsp-Xcc LOS and c) mIONPsp-HyNic-4FB-OVA after 3 h incubation. Cells’ 
nuclei were stained with Hoechst blue and lysosomes and endosomes with lysotracker green. b,d) UV–vis absorption and fluorescence spectrum of 
b) rhodamine-labeled mIONPsp-Xcc LOS and d) mIONPsp-HyNic-4FB-OVA. Scale bar = 20 × 10−6 m.
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been investigated previously. Hence, for comparison of adjuvant 
properties, C57BL/6 mice were immunized subcutaneously (s.c.) 
with OVA (5 µg) alone or with OVA (5 µg) + E. coli LPS (1 µg), 
OVA (5 µg) + MPLA (1 µg), and OVA (5 µg) + Xcc LOS (1 µg) at 
days 0 and 14, and at day 21 week were challenged with 3 × 105 
B16-F10(OVA) cells, and tumor growth was monitored until they 
reached the limits of the established endpoint (Figure 5a). To 
evaluate the utility of the nanoparticle delivery, another group of 
mice was immunized with mIONPsp-HyNic-4FB-OVA formu-
lated with pathogen-mimicking mIONPsp-Xcc LOS as adjuvant. 
All animals vaccinated with the TLR4 agonists showed reduced 
tumor growth and provided survival benefits (median survivals 
of 34–38 d) compared to the OVA-treated (median survival of 
28 d) even with the low adjuvant doses (1 µg). Notably, despite 
a weaker capacity of Xcc LOS to induce IL-6 production in the 
J774A.1 macrophages, it proved to be as effective as adjuvant as 
the strong TLR4 ligand E. coli LPS and the clinically approved 
MPLA (Figure 5b,c). Compared to the nanoparticle-free treat-
ments, the immunization with mIONPsp-HyNic-4FB-OVA for-
mulated with pathogen-mimicking mIONPsp-Xcc LOS delayed 
longer the tumor growth (Figure 5d,e).
We investigated the immune mechanisms behind the 
enhanced antimelanoma response to the nanovaccines. To this 
end, systemic antibody responses as well as the induction of 
tumor antigen-specific cytotoxic T lymphocyte (CTL) effector and 
memory response were assessed. Blood samples were obtained 
and the production of OVA-specific IgG, IgG1, and IgG2 anti-
bodies in the circulation was evaluated by ELISA. The results 
showed that the TLR4 agonists elicited higher levels of anti-
bodies specific for OVA than immunization with antigen alone 
(Figure 6a). In particular, we observed the induction of the IgG2c 
isotype, which is typically implicated with enhanced protection 
in both infectious diseases and cancer and is not induced by the 
clinically approved aluminum adjuvants. Notably, mIONPsp-
HyNic-4FB-OVA formulated with mIONPsp-Xcc LOS elicited 
similar or lower levels of total IgG, IgG1, and IgG2c antibodies 
than the vaccines without mIONPsp vehicles. Although the 
increase in titers of antigen-specific antibodies in these immuni-
zations indicates immune adjuvant activity in these preparations, 
it does not explain the enhanced protection against the mela-
noma challenge provided the mIONPsp-based nanovaccines.
Contrasting with vaccination strategies aimed at gener-
ating antibody production, generating protective memory 
CD8+ T-cells has proven more difficult to achieve.[64] We there-
fore analyzed if the immunization with OVA + Xcc LOS and 
mIONPsp-HyNic-4FB-OVA formulated with pathogen-mim-
icking mIONPsp-Xcc LOS was able to drive antigen-specific 
CD8+ T-cell responses. For this, we monitored the frequency 
of OVA257-264 (SIINFEKL)-specific CD8+ T-cells by H-2Kb/SIIN-
FEKL dextramer staining and flow cytometric analysis. The 
highest frequency of SIINFEKL-specific CD8+ T-cells was found 
in mice immunized with OVA antigen delivered by mIONP-
HyNic-4FB-OVA and formulated with pathogen-mimicking 
mIONPsp-Xcc LOS (Figure 6b).
Following infection or vaccination, naive CD8+ T cells are 
primed in secondary lymph node by DCs and consequently 
proliferate and differentiate into effector and memory cells. 
The CD8+ memory T-cells divide into “effector memory” cells 
(TEM) and “central memory” (TCM) cells. TEM and TCM exhibit 
distinct functional abilities,[65] which intriguingly could poten-
tially be generated differently in response to the vaccines 
and nanovaccines and play a role in their different protective 
abilities. Whereas TEM are localized in peripheral nonlymphoid 
tissues (e.g., lung, liver, intestine), spleen, and blood and can 
Small 2019, 15, 1803993
Figure 5. Protective immunity against B10-F10(OVA) melanoma cells by the use of the different TLR4 agonist adjuvants coadministered with tumor 
antigen. a) Vaccination scheme. C57BL/6J mice were s.c. immunized with the indicated formulations (5 µg of OVA, 1 µg of TLR4 agonist per mouse, 
25–70 µg of IONP on day 0 and 14 and s.c. challenged with 3 × 105 B16-F10(OVA) cells per mouse on day 21. b–e) Average and individual tumor growth 
curves and Kaplan–Meier survival curves. The data show mean ± SEM from a representative experiment (n = 5–10) from 2 to 3 independent experiments.
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immediately recognize and kill the target virally infected/cancer 
cells, TCM cells are known to be able to traffic into lymph nodes 
directly from the blood and are thought to provide a sustained 
and robust CTL recall response to control subsequent disease 
challenges.
We analyzed the frequency of circulating SIINFEKL-
specific CD8+ TEM-cells (CD44+CD62Llow) and TCM-cells 
(CD44+CD62Lhigh) over time (t = 0, 7, 14, 21, 28, and 35 d). 
mIONPsp-vaccinated mice had much greater frequency of both 
antigen-specific TEM and TCM cells. The TEM population peaked 
at day 7 after the first vaccination and the levels increased 
drastically on day 35, i.e., after boost and tumor challenge 
(Figure 6c). The highest frequency of the SIINFEKL-specific 
CD8+ TCM-cells was observed on day 35 (Figure 6d). The results 
demonstrate that the nanovaccines generate more effectively 
protective memory CD8+ T cells.
2.6. The Adjuvant Properties of Xcc LOS Enhanced by 
Nanoparticle Delivery Confers 100% Protection against the 
B16-F10(OVA) Melanoma Cells When PD-L1 Expression 
is Abrogated in Tumor Cells
We next explored the effect of immunization combined with 
immune checkpoint inhibition at the level of the cancer cell 
using B16-F10(OVA) melanoma cells with silenced PD-L1. 
PD-L1 blockade achieves the same effects than knocking out 
PD-L1 in cancer cells as demonstrated previously. We used a 
protocol that uses CRISPR/Cas9 genome editing and lentiviral 
particles to generate the PD-L1-deficient B16-F10(OVA), as 
described before;[48,49] the abrogation of PD-L1 was confirmed 
by flow cytometry (Figure S10, Supporting Information). This 
genetically modified cell line, B16-F10(OVA) ΔPD-L1, was used 
in the prophylactic immunization assay (Figure 7a). C57BL/6 
mice were subcutaneously administered PBS or were vacci-
nated with OVA + Xcc LOS and mIONPsp-HyNic-4FB-OVA + 
mIONPsp-Xcc LOS (days 0 and 14) and inoculated with 2 × 106 
B16-F10(OVA) ΔPD-L1 cells (day 21). All the mice treated with 
PBS developed melanoma tumors within 10 d. As PD-L1 abro-
gation decreases tumor cell growth, we first confirmed that the 
tumor growth kinetics following inoculation of 2 × 106 B16-
F10(OVA) ΔPD-L1 and inoculation of a lower dose (3 × 105) of 
B16-F10(OVA) cells was equivalent for mice treated with PBS. 
However, in the case of mice immunized with OVA + Xcc LOS, 
mice remained tumor free for 20 d and 40% did not develop 
tumor past 100 d after the challenge with B16-F10(OVA) 
ΔPD-L1 cells, compared to all the mice developing tumor by 
day 20 after the challenge with the B16-F10(OVA) cells. In the 
case of mice immunized with mIONPsp-HyNic-4FB-OVA + 
mIONPsp-Xcc LOS 100% of the animals were free of tumor 
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Figure 6. Immunization with the mIONPsp-based vaccines triggers a higher-level tumor antigen-specific cytotoxic T lymphocyte (CTL) effector 
responses. a) OVA-specific serum IgG1, IgG2c, and total IgG titers 2 weeks after s.c. challenge with 3 × 105 B16-F10(OVA) cells (day 35). b) Analysis of 
frequency of circulating OVA257-264 (SIINFEKL)-specific CD8+ T-cells isolated from blood. c,d) Frequency of SIINFEKL-specific CD8+ TEM and TCM cells. 
TCM cells are defined as CD3+CD8+CD62L+CD44+ and TEM as CD3+CD8+CD62L−CD44+. Data presented as mean ± SEM. n = 5 mice per group. ****P < 
0.0001, ***P < 0.001, **P < 0.01, *P < 0.05 by a) one-way ANOVA followed by Tukey’s test and b–d) two-way ANOVA followed by Bonferroni’s test.
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110 d after the challenge with B16-F10(OVA) ΔPD-L1 cells 
(Figure 7b,c,e). Furthermore, analysis of SIINFEKL-specific 
CD8+ T cells corroborated the enhanced protection against the 
melanoma cells (Figure 7d). Hence mIONPsp delivery com-
bined the permanent PD-L1 checkpoint blockade remarkably 
improved the efficacy of the vaccination.
To assess the longevity and efficiency of memory recall 
responses in the mIONPsp-vaccinated mice, we investigated 
the immune responses 100 d after the boosting immuniza-
tion. Mice received a recall immunization 103 d after the boost 
and the capacity to clear a rechallenge (2 × 106 B16-F10(OVA) 
ΔPD-L1 cells s.c. implanted on the right back on day 122) was 
investigated. Whereas the control mice developed melanoma 
tumors within 10–15 d, 100% of the mIONPsp-vaccinated 
mice remained tumor-free until the end of the experiment 
(day 139) (Figure 8b). We analyzed the frequency of circulating 
SIINFEKL-specific CD8+ T cells in the blood previous to the 
recall immunization. We did not detect SIINFEKL-specific cells 
neither within the CD8+ nor in the TCM cell population, com-
paring immunized mice with mice of the same age that had 
not been immunized/challenged with the melanoma cells. 
However, analysis of the TEM subset revealed that mice immu-
nized with mIONPsp-HyNic-4FB-OVA + mIONPsp-Xcc LOS 
had high levels of SIINFEKL-specific CD8+ TEM cells even 100 d 
after the first immunization (Figure 8c). To analyze the magni-
tude and quality of the memory response generated after the 
recall, we analyzed the frequency of circulating antigen-specific 
T cells. The frequencies of the SIINFEKL-specific CD8+ T cells 
in peripheral blood were high 5.9 ± 2.0% (n = 5) (compared to 
1.2 ± 0.5% at day 35 after the first boost and first tumor chal-
lenge). Antigen-specific TEM and TCM cell percentages were 
also rapidly increased after the recall, reaching the frequencies 
observed on day 35 after first immunization and boost, indi-
cating mIONPsp-based vaccines induced T-cell memory and 
effective recall responses.
To evaluate the quality of CD8+ T-cell responses, cellular 
extracts from spleen were cultured ex vivo and incubated 
with the antigenic peptide SIINFEKL for 5 h, and the IFN-γ 
and TNF-α intracellular production, as well as the degranula-
tion marker CD107a, were analyzed by flow cytometry. The 
data demonstrated that mice immunized with the nanopar-
ticles generate T lymphocytes with enhanced cytolytic activity 
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Figure 7. Protective immunity against B16-F10(OVA) melanoma cells with knocked-down expression of PD-L1 (B16-F10(OVA) ΔPD-L1). a) Vaccination 
scheme. C57BL/6J mice (n = 5) were s.c. challenged with 2 × 106 B16-F10(OVA) ΔPD-L1 cells 7 d after the last vaccination with 5 µg of OVA, 1 µg Xcc 
LOS per mouse, 25 µg of IONP). b) Average and e) individual tumor growth curves and c) Kaplan–Meier survival curves. d) Circulating SIINFEKL-
specific CD8+ T cells 35 d after the first immunization (2 weeks after tumor inoculation). **P < 0.01, *P < 0.05, ns, nonsignificant by one-way ANOVA 
followed by Tukey’s test. CR, fraction of complete tumor rejection.
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(Figure 8e,f). Also, the cells collected from the spleen showed 
significantly enhanced ability to release IFN-γ following ex vivo 
restimulation with SIINFEKL (over 48 h). Taken together, the 
results show the development of a potent and long lasting anti-
tumor immunity when combining mIONPsp-based vaccines 
with PD-L1 abrogation.
3. Conclusion
In summary, we have designed and developed a cancer vaccine 
platform based on pathogen-mimicking TLR4 agonist function-
alized nanostructures, which is significantly enhanced blocking 
the PD-1/L1 checkpoint. The system is composed of iron oxide 
NPs encapsulated in phospholipid micelles where the covalent 
ligation of antigen was achieved by aniline-catalyzed hydrazone 
ligation, and the LOS derived from the plant pathogen Xcc as 
TLR4 agonist was adhered by hydrophobic interactions. We 
provided the first evidence that Xcc LOS elicits as adjuvant as 
potent immune responses as MPLA (FDA-approved TLR4 ago-
nist) for the development of anticancer vaccines. However, this 
study also showed that unlike MPLA, the structurally unique Xcc 
LOS allows effective interaction with certain NP-filled micelles 
for the generation of stable pathogen-mimicking nanostruc-
tures with size, charge, and hydrophobicity ideal for lymph node 
delivery. The nanostructures with the best properties (size, sta-
bility, toxicity profile, and immune response) encapsulated the 
type of iron oxide NPs for which previous studies have shown 
effective in vivo tracking by multimodal imaging,[21,66] and 
ability to potentiate other cancer immunotherapies approaches 
Figure 8. Tumor protection and rapid activation of the immune system upon recall of mIONPsp-based vaccines (n = 5). a) 103 d after the first tumor 
inoculation, T-cell memory was recalled with the nanovaccines (same antigen/adjuvant concentrations). Five days after, a tumor rechallenge with 
2 × 106 B16-F10(OVA) ΔPD-L1 cells was carried out. At day 17 after the second tumor challenge, mice were sacrificed and blood and spleens were col-
lected for further immune analysis. b) Average tumor growth curves. c,d) SIINFEKL-specific CD8+, TEM and TCM cell percentages c) before and d) after 
recall injection. e,f) Intracellular IFN-γ and TNF-α production and CD107a expression after 5 h of incubation with 10 µg mL−1 of SIINFEKL peptide. 
g) Extracellular IFN-γ production after 48 h of incubation with the peptide. ***P < 0.001, **P < 0.01, *P < 0.05, ns, nonsignificant by c,d) two-way 
ANOVA followed by Bonferroni’s test and e–g) one-way ANOVA followed by Tukey’s test.
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such as DC-based vaccination[32] and macrophage polariza-
tion into proinflammatory M1 phenotypes.[33] We showed that 
aniline-catalyzed hydrazone ligation enables highly efficient, 
monitorable, and stable covalent conjugation of tumor antigen 
for creating the multifunctional nanovaccines under physi-
ological conditions at micromolar concentrations. The designed 
nanovaccines led to enhanced protection against highly aggres-
sive and poorly immunogenic B16-F10 murine melanomas, and 
by abrogation of PD-L1 expression in the melanoma cells, they 
achieved complete tumor rejection in 100% of the immunized 
mice. Taken together, the study reveals the potential of Xcc LOS 
for development of anticancer vaccines and shows the general 
utility of creating nanovaccines based on pathogen-mimicking 
nanostructures and the hydrazone ligation reaction for antigen 
binding, as well as the importance of PD-L1 blockade for the 
significant “upgrading” vaccines exploiting TLR4 agonists.
4. Experimental Section
Bacterial Growth and LOS Extraction: The lipooligosaccharide from 
Xcc was extracted and purified from dried cells as described in the 
Supporting Information and reported previously.[55,67]
Synthesis and Characterization of Pathogen-Mimicking Micelles 
Encapsulating Iron Oxide Nanoparticles/Quantum Dots: Hydrophobic 
spherical IONP (IONPsp) and cubic IONP (IONPc) were prepared 
according to published procedures.[68,69] To prepare control micelles and 
micelles for antigen conjugation, 1 mg of IONPsp, IONPc, or QDs and 
2 mg of PEG phospholipids (phospholipid–PEG–OMe when preparing 
the micelles incorporating LPS/LOS and phospholipid–PEG–NH2 for 
the conjugation of antigen) were dissolved in 100 µL and 200 µL of 
chloroform respectively, combined in a 4 mL round-bottomed flask 
with 100 µL of chloroform and allowed to evaporate overnight at RT. 
The LOS- and LPS-coated micelles were prepared as described above 
with 0.2 mg of LOS or LPS dissolved in 100 µL of chloroform. For 
fluorescent labeling of the micelles 5% of 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine-N-lissamine rhodamine B sulfonyl-ammonium 
salt was added to the phospholipid solution. The flask was placed 
in a water bath at 80 °C for 30 s, after which the resulting lipid film 
containing the nanoparticles was hydrated by adding 1 mL of MilliQ 
water. This solution was centrifuged (5000 × g, 5 min for mIONPsp 
and mQDs; 300 × g, 5 min for mIONPc) and passed through a 0.45 µm 
sterile syringe filter to remove any nonsoluble or large particles. Then, the 
micelles were centrifuged (108 600 × g, 50 min for mIONPsp, 88 200 × g, 
25 min for mIONPc; 108 600 × g, 45 min for mQDs); the supernatant 
was discarded (or analyzed for LPS/LOS content) and washed with 
MilliQ water to remove empty micelles and free ligands (three cycles). 
Finally, the pellet was dissolved in 400 µL of MilliQ water (or 10 × 10−3 m 
phosphate buffered saline, PBS) and the nanoparticle-filled micelles 
were stored at 4 °C. Quantification of the iron concentration in the 
micelles was carried out by inductively coupled plasma atomic emission 
spectroscopy (ICP-AES) analysis. ICP-AES analyses were carried out on a 
Perkin Elmer Optima 5300 DV (Perkin Elmer, Santa Clara, CA, USA). The 
concentration of the QDs was determined from the optical absorption 
spectra according to Yu et al.[70] For this purpose, the absorption spectra 
of the mQDs solutions in the 200–800 nm range were recorded on a 
V-630Bio Spectrophotometer (JASCO Analytical Instruments).
Transmission electron microscopy (TEM) studies were performed 
using a JEOL JEM-2011 electron microscope operating at 120 kV. 
The samples were prepared by deposing a drop of a solution of the 
hydrophobic nanoparticles (1 mg mL−1 in THF) onto Pelco 150 mesh 
grid (Ted Pella) and allowing it to dry. For the characterization of the 
hydrophilic samples, TEM grids were polarized using a Quorum 
technologies K100X glow discharge system. Nanoparticle size was 
determined from the TEM images measuring a minimum of 200 
nanoparticles with the ImageJ software. Hydrodynamic diameter and 
ζ-potential of the micelles were measured using a Z-Sizer (Malvern 
Nano-Zs, UK). To determine the stability, mIONPsp-Xcc LOS and 
mIONPsp-HyNic-4FB-OVA were dissolved in 10 × 10−3 m PBS and 
the hydrodynamic diameter analyzed by Z-Sizer immediately after 
purification and over a 4 week period. To measure the ζ-potential, the 
samples were dissolved in 10 × 10−3 m NaCl and analyzed by Z-sizer.
Conjugation of OVA Antigen to mIONPsp: First, mIONPsp micelles 
were conjugated to HyNic (6-hydrazinonicotinamide acetone hydrazone) 
by coupling the succinimidyl ester (S-HyNic) to the amino groups of 
DSPE–PEG–amine. mIONPsp micelles (0.5–3 × 10−6 m) in 50 × 10−3 m 
NaPi buffer (pH 7.4) were reacted with a 1 × 10−3 m HyNic solution 
in CH3CN (NP:HyNic molar ratio ≈2000:1). The reaction mixture 
was stirred overnight (≈14 h) at room temperature and the product 
was purified using a desalting column and a 0.5 mL centrifugal filter 
(100 kDa MW cutoff). Ovalbumin was modified with FB (succinimidyl 
4-formylbenzoate). For this purpose, a 450 × 10−6 m endotoxin-free OVA 
solution in 50 × 10−3 m NaPi buffer (pH 7.4) was added to a 1 × 10−3 m 
FB solution in dimethyl sulfoxide (DMSO) (550 µL total volume) and 
stirred overnight at room temperature. Purification was carried out using 
a desalting column and a 4 mL centrifugal filter (10 kDa MW cutoff). The 
product was stored at 4 °C until further use. Finally, the HyNic-modified 
mIONPsp (≈0.5–3 × 10−6 m) in 50 × 10−3 m NaPi buffer (pH 6.2) were 
reacted with the FB-modified OVA (20–30 × 10−6 m) in the presence of 
100 × 10−3 m aniline. The reaction mixture was stirred overnight at room 
temperature and the product was purified by a desalting column and a 
0.5 mL centrifugal filter (100 kDa MW cutoff). The obtained product was 
centrifuged at 17 400 × g for 20 min and the pellet washed with MilliQ 
water to remove unbound OVA.
Quantification of LOS/LPS Loading: The amount of LOS/LPS 
incorporated into the micelles was determined using a dose response 
curve obtained by measuring the amount of IL-6 released by J774A.1 
macrophages stimulated overnight with the free ligands as a function 
of concentration. The amount of unbound LOS molecules present 
in each of the supernatants from each of the centrifugation cycles 
used for the purification of the NP-filled micelles was extrapolated 
from his calibration curve by measuring the amount of IL-6 released 
when the macrophages were incubated with the supernatants. For this 
purpose, a dose response calibration curve was obtained with Xcc LOS 
concentrations ranging from 3 to 36 × 10−6 m. IL-6 was measured in 
cell supernatants using sandwich ELISA following the manufacturer’s 
instructions (vide infra). The amount of LPS was also determined using 
the FDA-approved limulus amebocyte lysate (LAL) test. For this purpose, 
the analysis of LPS in the supernatants was performed using a Pierce 
LAL chromogenic endotoxin quantitation kit (Thermofisher) following 
the instructions given by the manufacturer. The assay was performed in 
aseptic conditions. Briefly, 50 µL of test sample were added to the test 
well in the 96-well plate at 37 °C and, incubated for 5 min after which 
the LAL reagent was added to each well. Following 10 min incubation, 
100 µL of substrate solution was added, stirred and incubated for 6 min. 
Then, 25 µL of stop reagent solution was added and the absorbance at 
405 nm was immediately measured using a Varioskan LUX multimode 
plate reader (Thermo Fisher). The concentration of LPS in the unknown 
samples was determined using a calibration curve.
Xcc LOS Release Studies: Xcc LOS content in the micelles was 
measured immediately after purification and after 1 or 2 weeks. 
mIONPsp-Xcc LOS nanoparticles were centrifuged (108 600 g × g, 
50 min) and the supernatant was analyzed for Xcc LOS as described 
above.
Cell Viability and Cytokine Production Experiments: The J774A.1 mouse 
macrophage cell line was obtained from the American Type Culture 
Collection (ATCC) and was grown at 37 °C in a humidified atmosphere 
of 5% CO2 using DMEM supplemented with 10% FBS and 1% P/S. Cell 
viability was determined using an 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl 
tetrazolium bromide (MTT) assay. Briefly, cells were administered with 
100 µL per well of an MTT solution diluted in medium and incubated for 
1 h at 37 °C, after which supernatants were discarded and MTT crystals 
dissolved in 200 µL per well of DMSO. The absorbance of the wells was 
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measured using a TECAN Genios Pro 96/384 multifunction microplate 
reader at 550 nm and data represented as the cell viability compared 
to control wells. For obtaining the BMDC primary culture, C57BL/6J 
mice (6–12 weeks old) were sacrificed by cervical dislocation and intact 
femurs and tibiae of hind limbs were removed aseptically as described in 
the Supporting Information and reported elsewhere.[71]
Quantification of Cytokine and Antibody Production by ELISA: Cytokines 
were measured in cells’ supernatants using IL-6, IL-12, or TNF-α 
sandwich ELISA. A four-parameter logistic standard curve was generated 
using Graph Pad prism 5 and used to get the cytokines concentrations. 
Results are expressed as mean ± SEM in pg mL−1 or ng mL−1. Anti-OVA 
IgG antibodies were measured in blood serum using indirect ELISA. 
The results were expressed as the log10 value of the reciprocal of the 
endpoint dilution that gave an optical density (O.D.) higher than the 
chosen cutoff, after the subtraction of background levels.
Analysis of DCs’ Maturation Markers by Flow Cytometry: After overnight 
incubation with the different stimuli, 96-well plates containing the 
BMDCs were centrifuged (700 × g, 5 min, 4 °C) and supernatants were 
removed. Cells were stained with Alexa Fluor 488-labeled anti-CD11c, 
Brilliant Violet-labeled anti-CD80, PE-labeled anti-CD86, and APC-
labeled anti-PD-L1 antibodies. Finally, cells were transferred to cytometry 
tubes by smooth pipetting. The expression of the different markers 
was analyzed using a FACS Canto II flow cytometer. BMDCs were 
electronically gated based on the forward and side scatter parameters 
and the not-single events left out based on forward area and height 
scatter parameters. DCs were gated based on positive staining for 
CD11c population marker and the expression of the chosen maturation 
markers was analyzed within this population (Figure S11a, Supporting 
Information). Results were expressed as mean ± SEM of the MFI of each 
maturation marker of three independent experiments.
Fluorescence Microscopy: J774A.1 cells were seeded in an Ibidi µ-Slide 
VI0.4 at a density of 30 000 cells per well in supplemented DMEM and let 
to adhere overnight in an incubator maintained at 37 °C and 5% CO2. 
The day after, the medium was removed and cells were administered 
with 1 µg mL−1 Hoechst blue to stain the nuclei and incubated for 
30 min. Cells were washed with PBS three times to remove unbound dye 
and then incubated with ≈200 × 10−9 m mIONPsp(Rho)-HyNic-4FB-OVA 
or mIONPsp(Rho)-Xcc LOS for 3 h. Cells were washed again and stained 
with 1 × 10−3 m Lysotracker green, incubated for 30 min, washed with 
PBS and finally images were taken using a ZEISS Axio Observer inverted 
microscope.
In Vivo Studies: Animals were cared for and handled in compliance 
with the Guidelines for Accommodation and Care of Animals (European 
Convention for the Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes) and internal guidelines, 
and all the experimental procedures were approved by the appropriate 
local authorities. All animals were housed in ventilated cages and fed on 
a standard diet ad libitum.
Assessment of Antitumor Effect: C57BL/6 mice (6−8 weeks old) 
were immunized subcutaneously in the flanks twice with an interval 
of 2 weeks between injections (100 µL, 50 µL per flank, 1 µg of TLR4 
ligands, 5 µg of OVA and ≈25–70 µg of IONP per mice). On day 21 
after first immunization, 3.5 × 105 B16-F10(OVA) cells or 2 × 106 
B16-F10(OVA) ΔPD-L1 cells diluted in PBS:Matrigel (1:1) were injected 
in the right back. Animals were monitored for tumor growth using an 
electronic digital caliper 779A series (Starrett). Criteria for humane 
endpoint included tumors greater than 1.5 cm diameter and ulceration. 
Results were expressed as mean ± SEM of at least five mice per 
group. Blood was taken (50 µL) at several time points after the first 
immunization for analyzing the generated immune response. In the 
case of antibodies production, blood was diluted in PBS and centrifuged 
(13 000 × g, 5 min) to separate the serum (supernatant) from blood 
cells (pellet). Blood sera were stored at −20 °C until its analysis by 
ELISA. In order to analyze the circulating cellular response, blood was 
diluted up to 4 mL in cold PBS. After centrifugation (1028 × g, 5 min at 
4 °C), the pellet was resuspended in 2 mL of commercial RBC lysing 
buffer and incubated at RT. After washing the cell suspensions twice 
with 5% FBS in PBS via centrifugation, cells were resuspended in 
complete RPMI-1640, ready for further analysis. Secondary lymphoid 
organs such as spleens were also harvested for the analysis of local 
cellular response. Briefly, spleens were harvested and perfused with 
tissue dissociating mix (3 mL of collagenase/DNase I diluted in 
RPMI-1640 medium), cut into small pieces and incubated for 30 min 
at RT in a sterile Petri dish. The reaction was stopped with 36 µL of 
500 × 10−3 m EDTA and organs were dissociated with the plunger of 
a syringe. RBC lysis was performed as previously described and the 
resulting cell suspensions were resuspended in complete RPMI-1640. 
Primary immune cells were analyzed for CD8+ T cells, TCM and TEM cells 
specific for the OVA epitope SIINFEKL; extracellular and intracellular 
TNF-α and IFN-γ production and CD107a degranulation marker 
expression were also analyzed. The quantification of extracellular IFN-
γ production was performed by seeding 8 × 105 splenocytes per well, 
followed by incubation over 48 h with 10 µg mL−1 of SIINFEKL peptide 
and analyzing the supernatants by sandwich ELISA, as described above. 
For flow cytometry assays, 1 × 106 splenocytes or peripheral blood cells 
were placed in round-bottom 96-well plates and stained with different 
antibodies. SIINFEKL-specific T cells were stained with Brilliant Violet 
421-labeled anti-CD3, PE.Cy7-labeled anti-CD8, APC-labeled anti-CD44, 
FITC-labeled anti-CD62L and PE-labeled H-2kb-OVA257−264 dextramer 
(Immudex). SIINFEKL specific cell percentage was analyzed in the 
CD8+ T cell population (CD3+ and CD8+ double positive); in the TCM cell 
population (cells showing a phenotype of CD44low and CD62Llow within 
CD3+ and CD8+ double positive population); and in the TEM population 
(CD44high and CD62Llow) Figure S11b, Supporting Information). To study 
intracellular TNF-α and IFN-γ and the expression of the degranulation 
marker CD107a, cells were placed in 100 µL of RPMI-1640 medium in 
the presence of Golgi Stop (BD Biosciences), PE-labeled anti-CD107a 
and 10 µg mL−1 SIINFEKL peptide. After 5 h of incubation at 37 °C, 
cells were washed twice and stained with the surface markers Brilliant 
Violet 421-labeled anti-CD3, Brilliant Violet 510-labeled anti-CD4 
and FITC-labeled anti-CD8. Then, cells were fixed and permeabilized 
(cytofix/cytoperm fixation and permeabilization kit, BD Biosciences), 
after which intracellular cytokine staining was performed (APC-labeled 
anti-INF-γ and PE.Cy7-labelled anti-TNF-α). T cells were gated based 
on double positive for CD3 and CD8 markers, excluding CD4+ cells if 
needed. Results were represented as IFN-γ and CD107a double positive 
or TNF-α positive cell percentage of total CD3+ CD8+ T cells. Isotype 
controls were added when needed but were not included in the figures 
for clarity purposes. Results were expressed as mean ± SEM of five 
mice per group of immunization, analyzed individually, and compared 
to unstimulated wells.
Statistical Analysis: All data presented were expressed as mean ± 
SEM. The differences between the control and the experimental groups 
were assessed using one- or two-way ANOVA followed by Tukey’s test or 
Bonferroni’s test (GraphPad Prism, GraphPad Software, La Jolla, CA). 
P values of less than 0.05 were considered statistically significant.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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